The overlap phenotype: the (missing) link between asthma and COPD

[1]  M. Miravitlles,et al.  Clinical Phenotypes of COPD: Identication, Denition and Implications for Guidelines , 2012 .

[2]  Joyce D. Schroeder,et al.  The clinical features of the overlap between COPD and asthma , 2011, Respiratory research.

[3]  Gesepoc Workgroup.  [Moving towards a new focus on COPD. The Spanish COPD Guidelines (GESEPOC)]. , 2011, Archivos de bronconeumologia.

[4]  Grupo de Trabajo de GesEPOC.  Hacia un nuevo enfoque en el tratamiento de la EPOC. La Guía Española de la EPOC (GESEPOC) , 2011 .

[5]  M. Miravitlles.  Arguments in favor of inhaled corticosteroids in COPD by phenotype instead of by severity. , 2011, Archivos de bronconeumologia.

[6]  M. Miravitlles.  Corticoides inhalados en la EPOC por fenotipo en lugar de por gravedad. Argumentos a favor , 2011 .

[7]  T. Haahtela,et al.  Overlap Syndrome of Asthma and COPD Predicts Low Quality of Life , 2011, The Journal of asthma : official journal of the Association for the Care of Asthma.

[8]  Edwin K Silverman,et al.  Chronic obstructive pulmonary disease phenotypes: the future of COPD. , 2010, American journal of respiratory and critical care medicine.

[9]  L. Fabbri,et al.  Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up. , 2010, The Journal of allergy and clinical immunology.

[10]  T. Welte,et al.  Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. , 2009, American journal of respiratory and critical care medicine.

[11]  David G. Anderson,et al.  Targeted treatment in COPD: a multi-system approach for a multi-system disease , 2009, International journal of chronic obstructive pulmonary disease.

[12]  P. Gibson,et al.  The overlap syndrome of asthma and COPD: what are its features and how important is it? , 2009, Thorax.

[13]  E. Bleecker,et al.  Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility. , 2008, Pulmonary pharmacology & therapeutics.

[14]  Anand A. Dalal,et al.  Burden of concomitant asthma and COPD in a Medicaid population. , 2008, Chest.

[15]  M. Decramer,et al.  Bronchodilator responsiveness in patients with COPD , 2008, European Respiratory Journal.

[16]  D. Niewoehner,et al.  Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: A prospective study , 2008, Therapeutic advances in respiratory disease.

[17]  Gianna Camiciottoli,et al.  Identification of a predominant COPD phenotype in clinical practice. , 2008, Respiratory medicine.

[18]  P. Barnes,et al.  Inflammation, Oxidative Stress and Systemic Effects in Mild Chronic Obstructive Pulmonary Disease , 2007, International journal of immunopathology and pharmacology.

[19]  I. Pavord,et al.  Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial , 2007, European Respiratory Journal.

[20]  I. Pavord,et al.  Multi‐dimensional phenotyping: towards a new taxonomy for airway disease , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[21]  I. Pavord,et al.  Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease , 2005, Thorax.

[22]  R. Perng,et al.  Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment. , 2004, Chest.

[23]  M. Saetta,et al.  Neutrophil chemokines in severe exacerbations of chronic obstructive pulmonary disease: fatal chemo-attraction? , 2003, American journal of respiratory and critical care medicine.

[24]  Joan B Soriano,et al.  The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. , 2003, Chest.

[25]  S. Spencer,et al.  Bronchodilator reversibility testing in chronic obstructive pulmonary disease , 2003, Thorax.

[26]  L. Fabbri,et al.  Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. , 2001, American journal of respiratory and critical care medicine.

[27]  L. Fabbri,et al.  Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[28]  I. Pavord,et al.  Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial , 2000, The Lancet.

[29]  D. Postma,et al.  Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample. , 1999, American journal of respiratory and critical care medicine.

[30]  D. Niewoehner,et al.  Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. , 1999, The New England journal of medicine.

[31]  S. Wenzel,et al.  Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. , 1997, American journal of respiratory and critical care medicine.

[32]  L. Fabbri,et al.  Airway eosinophilia in chronic bronchitis during exacerbations. , 1994, American journal of respiratory and critical care medicine.

[33]  M. Miravitlles.  The overlap syndrome between asthma and COPD: implications for management , 2011 .

[34]  A. Agustí,et al.  Fenotipos clnicos de la EPOC , 2010 .

[35]  M. Miravitlles.  [Individually-tailored treatment of chronic obstructive pulmonary disease: a proposed change]. , 2009, Archivos de bronconeumologia.

[36]  M. Miravitlles.  Tratamiento individualizado de la EPOC: una propuesta de cambio , 2009 .

[37]  Sean Keenan,et al.  Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. , 2007, Canadian respiratory journal.

[38]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[39]  F. Maltais,et al.  Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease--2003. , 2003, Canadian respiratory journal.

[40]  R. Djukanović,et al.  The relationship between airways inflammation and asthma severity. , 2000, American journal of respiratory and critical care medicine.